BioScience Managers – Page 21 – BioScience Managers

ADC BIO WILL BE PRESENTING AT 9TH ANNUAL WORLD ADC LONDON CONFERENCE

22nd February 2019/in BioScience Managers

Value Proposition of Integrated ADC Manufacturing Processes – Use of Economic Modelling-Poster will be presented at 9th Annual World ADC. Abstract Development and manufacture of biologic-drug conjugates involves a complex supply chain of multiple, different specialised contracted cGMP facilities. CDMOs have simplified project & contractual arrangements either forming supplier collaborations or acquiring specialised facilities […]

Super-fast-acting Prandial Insulin Product Receives £0.5m Innovate UK Boost

13th February 2019/in BioScience Managers

Super-fast product addresses critical unmet need in development of next generation artificial pancreas systems” “Novel formulation significantly accelerates absorption of insulin post injection – accelerating the onset of glucose lowering.” Cambridge, UK., 13 February 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for […]

How Forward Thinking and New Approaches Will Drive Up Efficiency

13th February 2019/in BioScience Managers

Charlie Johnson, CEO of biotechnology company ADC Bio, explains how substantial cost savings and faster time to market is achievable through the novel concept of combining the bioconjugation and purification steps. Charlie Johnson – CEO, ADC Bio As an advanced manufacturing concept, integrated bioconjugation is highly promising – and is now under development – with the […]

AVITA Medical Second Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update

31st January 2019/in BioScience Managers

Recent Highlights • Pre-launch U.S. product sales of A$1.1 million in second quarter • Successful preparation for U.S. national market launch in January 2019 • 26 abstracts highlighting RECELL® System clinical and economic benefits accepted for presentation at multiple burn conferences, including the American Burn Association (ABA) 51st Annual Meeting • A$41.7 million equity financing […]

Second positive phase 1 trial data for XF-73

28th January 2019/in BioScience Managers

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Second positive […]

AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting

28th January 2019/in BioScience Managers

RECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019 Valencia, Calif., USA, and Melbourne, Australia, 29 January 2019 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company,today announced that 26 abstracts highlighting theclinical and cost savings benefits of the RECELL® Autologous Cell Harvesting Device […]

Destiny Pharma awarded significant new grant funding up to £1.6 million under new UK-China AMR programme

25th January 2019/in BioScience Managers

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma […]

Destiny Pharma notes UK 5-year action plan on AMR

24th January 2019/in BioScience Managers

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma notes release of UK Government’s Vision and 5-year action plan to help tackle anti-microbial resistance (AMR), which includes additional investment in innovation Government’s plan consistent with Destiny Pharma’s objective of developing novel anti-infectives from its proprietary XF platform. Brighton, United Kingdom – 24 January 2019 – Destiny Pharma (AIM: […]

AVITA Medical Announces Results of Extraordinary General Meeting

14th January 2019/in BioScience Managers

Shareholders approve 2nd Tranche of December 2018 equity placement Valencia, Calif., USA, and Melbourne, Australia, 14 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, announce the results of the votes and the proxies received in […]

AVITA Medical Announces U.S. National Market Launch of RECELL® System

8th January 2019/in BioScience Managers

Strong market response to the RECELL System approval in advance of U.S. launch with 36 burn centers actively reviewing the product or placing commercial orders Valencia, Calif., USA, and Melbourne, Australia, 8 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has commenced the U.S. national […]

Pages